Assignee
ORIGENIS GMBH
DE·4 granted patents·5 pending applications·4 citations·filing 2013–2025
Top patents by PatentIndex Score
9 records- 0169US10000482B2Kinase inhibitorsORIGENIS GMBH·Filed 2013·Granted Jun 19, 2018·2 cites·21 claims
- 0269US9637491B2Pyrazolo[4,3-D]pyrimidines as kinase inhibitorsORIGENIS GMBH·Filed 2013·Granted May 2, 2017·2 cites·26 claims
- 0366US2025361237A11,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune diseaseORIGENIS GMBH·Filed 2025·Application pending·0 cites
- 0462US10752624B2Kinase inhibitorsORIGENIS GMBH·Filed 2018·Granted Aug 25, 2020·0 cites·7 claims
- 0556US12384788B21,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune diseaseORIGENIS GMBH·Filed 2020·Granted Aug 12, 2025·0 cites·20 claims
- 0652US2025019382A1Novel inhibitors of cyclin-dependent kinasesORIGENIS GMBH·Filed 2022·Application pending·0 cites
- 0749US2025144105A1Cdk9 inhibitorsORIGENIS GMBH·Filed 2023·Application pending·0 cites
- 0847US2023373985A1Kinase modulators and methods of use thereofORIGENIS GMBH·Filed 2021·Application pending·0 cites
- 0944US2022380374A11,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune diseaseORIGENIS GMBH·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →